Danny Jeyaraju
About Danny Jeyaraju
Danny Jeyaraju is a Senior Principal Scientist at Bristol Myers Squibb with extensive experience in translational science and biomarker discovery in hematology.
Current Role at Bristol Myers Squibb
Danny Jeyaraju currently serves as a Senior Principal Scientist at Bristol Myers Squibb. He began this role in June 2023. In his position, he works primarily with translational science and biomarker discovery in hematology. His extensive background and expertise enhance his responsibilities in late-stage translational leads and biomarker scientist roles for hematology-related therapies.
Previous Positions at Bristol Myers Squibb
Before his current role, Danny Jeyaraju worked as a Principal Scientist at Bristol Myers Squibb from 2021 to 2023. During his two-year tenure, he provided crucial insights and strategic input into therapeutic projects. His contributions in Summit, New Jersey significantly impacted ongoing and new research initiatives.
Career at Celgene
Danny Jeyaraju had notable positions at Celgene, initially serving as Scientist II from 2017 to 2020 for three years, and then advancing to Senior Scientist for two months in 2020-2021. In these roles, he concentrated on translational science and biomarker discovery, contributing to significant projects in hematology. His work in Summit, NJ, laid a strong foundation for his subsequent roles and achievements in the field.
Academic and Early Career Background
Danny Jeyaraju began his distinguished career in academia. From 2012 to 2016, he was a Postdoctoral Fellow at the University of Toronto. Prior to that, he worked as a Scientific Associate at the Princess Margaret Cancer Center, University Health Network, from 2016 to 2017. His academic excellence is marked by his Ph.D. in Neurobiology from Université Laval (2007-2012) and a Master of Science (MSc) from the same institution (2005-2006).
Specializations in Translational Science and Hematology
Danny Jeyaraju's primary expertise lies in translational science and biomarker discovery, specifically within hematology. He has led late-stage translational and biomarker projects for fedratinib (Inrebic) and luspatercept (Reblozyl) in myelofibrosis, focusing on enhancing therapeutic responses and outcomes. His specialized knowledge and experience make him a valuable asset in the field of hematology therapeutics.